Category:
Prophylactic Biological Products
CAS NO:
357336-20-0
Standard:
ChP,USP,BP,EP,JP,
Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the potential treatment of neurological disorders, namely epilepsy and neuropathic pain. By December 2003, UCB reported that phase II epilepsy trials had begun
Brivaracetam is a synthetic antiepileptic drug derived from levetiracetam, featuring high affinity for SV2A protein. Molecular formula: C11H16N2O2; CAS No.: 89457-30-9.
Contraindicated in patients with hypersensitivity to brivaracetam or levetiracetam. Store below 25°C in dry conditions. Monitor for CNS depression and behavioral changes during clinical use.